Latest news with #BhanuPrakash
NDTV
3 days ago
- Politics
- NDTV
Tirupati Board Suspends 4 Non-Hindu Employees, Members Welcome Decision
The Tirumala Tirupati Devasthanams (TTD), the administrative body that oversees the Sri Venkateswara Temple in Andhra Pradesh's Tirumala, suspended four employees on Saturday over allegations that they were following religions other than Hinduism, which is a direct violation of the institution's code of conduct. The TTD's decision comes in the wake of internal inquiries and a report submitted by its Vigilance Department. The employees' alleged practice of non-Hindu religious faiths is considered a breach of the institution's code of conduct, which mandates that individuals employed within the TTD system must adhere to the tenets of the Hindu faith in both conduct and practice. "In this context, after examining the report submitted by the TTD Vigilance Department, action was taken against them as per the rules and the four employees were immediately suspended," stated a press release issued by the Chief Public Relations Officer (CPRO) of TTD, Tirupati. The TTD has a long-standing rule, reinforced in 2007, which mandates only Hindu employees for its workforce. Bhanu Prakash, BJP TTD Board member supported the suspension and alleged that these employees lacked faith in Hinduism. He said they were using the deity's resources while maintaining faith in other religions. He said that their struggle would continue until the last non-Hindu employee is removed. In a meeting chaired by TTD Chairman B R Naidu, the Board decided to transfer the non-Hindu employees to other government departments or offer them voluntary retirement (VRS). Earlier this July, the Board had suspended its Assistant Executive Officer (AEO) with immediate effect for allegedly practising another faith in his hometown in Tirupati district. In February this year, the TTD Board took action against 18 non-Hindu employees, who allegedly followed other religions despite taking an oath to uphold and follow the Hindu faith when they joined. All of them were barred from taking part in religious activity of the temple and take a transfer to positions that are not connected to the temple.
Time of India
6 days ago
- Business
- Time of India
Private Equity infuses ₹4,900 cr in Indian Healthcare with 33 deals in Q2 CY25
New Delhi: In the second quarter of calendar year (CY) 2025, in the Indian Healthcare sector global and homegrown private equity firms have deployed a capital of around ₹4,900 crore ($580 million) in 33 deals spanning across Hospitals. Pharma and HealthTech, among others. According to a report from Grant Thornton Bharat, 'in Q2 2025 the Indian Pharma and Healthcare sector recorded a total of 33 PE deals of $580 million.' Against the previous quarter Q2 deal volumes declined by 21 per cent, while values saw a modest 3 per cent uptick—driven by a few mid-sized investments and stands as the second-highest quarter by value since Q2 2024. 'For the quarter PE activity clustered around a few high-confidence, institutional-grade platforms, especially in pharma manufacturing and hospital chains, signalling investor preference for scale, visibility, and IPO readiness,' the report noted. Of the total 33 deals, HealthTech accounted for the highest number with 10 deals, followed by Wellness (7), Pharmaceuticals and Medical Devices (5 each), and Hospitals with 4 deals. Major investments for the period includes US-based General Catalyst 's seed round investment of $218 million (around $18,500 crore) investment in PB Healthcare and Advent International's $175 million investment in Felix Pharma for a 'significant minority stake.' 'In this quarter Pharma and biotech led in value, powered by capital raises and strategic cross-border moves, while hospitals and healthtech platforms continued to evolve along distinct, high-potential growth paths.,' said Bhanu Prakash, Partner and Healthcare Services Industry Leader, Grant Thornton. 'As preventive care and digital health gain ground, we expect sharper, more focused bets in the second half of the year,' he added.
Time of India
6 days ago
- Business
- Time of India
India's pharma & healthcare sector records transactions worth $1.3 bn in Q2
India's pharma and healthcare sector recorded 57 transactions valued at $1.30 billion in the quarter ended June, including IPO and QIP activity—reflecting a 20% drop in volumes and a 50% decline in values compared to the previous quarter, according to a report from Grant Thornton Bharat . Excluding public market activity, the quarter saw 56 deals worth $788 million, down 16% in volumes and 62% in values. Explore courses from Top Institutes in Select a Course Category Data Science PGDM Data Science CXO MBA Operations Management MCA Digital Marketing Product Management healthcare Artificial Intelligence Management Design Thinking others Cybersecurity Healthcare Leadership Finance Project Management Data Analytics Public Policy Others Technology Degree Skills you'll gain: Duration: 10 Months E&ICT Academy, Indian Institute of Technology Guwahati CERT-IITG Prof Cert in DS & BA with GenAI India Starts on undefined Get Details Skills you'll gain: Duration: 11 Months E&ICT Academy, Indian Institute of Technology Guwahati CERT-IITG Postgraduate Cert in AI and ML India Starts on undefined Get Details Skills you'll gain: Duration: 30 Weeks IIM Kozhikode SEPO - IIMK-AI for Senior Executives India Starts on undefined Get Details Skills you'll gain: Duration: 11 Months IIT Madras CERT-IITM Advanced Cert Prog in AI and ML India Starts on undefined Get Details Skills you'll gain: Duration: 10 Months IIM Kozhikode CERT-IIMK DABS India Starts on undefined Get Details Despite this moderation, the sector remained a key contributor to overall deal activity, accounting for 10% of volumes and 6% of values, according to the report. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Đây có thể là thời điểm tốt nhất để giao dịch vàng trong 5 năm qua IC Markets Tìm hiểu thêm Undo The report captures data for the first quarter till June 26 and hence does not capture the Torrent Pharma and JB Chemicals deal that was announced end of the month. Torrent will acquire 46.39% equity stake (on a fully diluted basis) of JB Chemicals through a share purchase agreement for Rs 11,917 crores at Rs 1,600 per share. The pharma and biotech segment led in terms of value, fuelled by large capital raises such as Biocon 's $523 million QIP and strategic cross-border M&A. Live Events Hospital platforms evolved along two tracks: consolidation by multispecialty giants and regional expansion by focused, single-specialty players. On the consumer front, HealthTech, Diagnostics, and Wellness segments made up nearly half of the deal volume, signalling sustained investor interest in digital platforms, home-based services, and preventive care. 'While deal activity in Q2 2025 moderated, investor confidence in India's pharma and healthcare ecosystem continues— especially in segments demonstrating scalability, innovation, and public market readiness,' said Bhanu Prakash, Partner and Healthcare Services Industry Leader, Grant Thornton. 'Pharma and biotech led in value, powered by capital raises and strategic cross-border moves, while hospitals and healthtech platforms continued to evolve along distinct, high-potential growth paths. As preventive care and digital health gain ground, we expect sharper, more focused bets in the second half of the year,' he said. M&A activity in Q2 remained stable in terms of volume, recording 23 deals, but saw a sharp 86% drop in deal values compared to the previous quarter— largely due to the absence of large platform acquisitions and a non-disclosure of deal values, with 74% of transaction values undisclosed. Domestic deals dominated the landscape, contributing 87% to deal volumes and 83% to overall values. Hospital platform consolidation was the key driver of domestic activity, while the pharma and biotech segments led in value terms. The top M&A deal of the quarter was Emcure Pharmaceuticals Ltd's acquisition of Zuventus Healthcare for $84 million. PE activity in the sector remained active in Q2 2025, recording 33 deals worth $580 million. While deal volumes declined by 21% compared to the previous quarter, values saw a modest 3% uptick—driven by a few mid-sized investments. Notable among these were General Catalyst's $218 million infusion into PB Healthcare and Advent International's $175 million stake in Felix Pharma. These two transactions together contributed significantly to value activity, making Q2 the second-highest quarter by value since Q2 2024. Despite the lower deal count, the segment continued to attract targeted capital, especially in hospital platforms and pharma-focused plays, reflecting investor confidence in scalable, essential healthcare models amid evolving global headwinds. Public market activity in the sector remained subdued in Q2 2025, with no IPOs recorded—marking a sharp contrast to the previous quarter, which saw three listings raise $503 million. However, QIP activity surged during the quarter, led by Biocon's $523 million QIP. This single transaction contributed nearly 40% of the total quarterly sector deal value, highlighting the continued reliance of large, established players on selective capital raises to fund growth and strengthen balance sheets amid a muted broader capital markets environment.
Hans India
01-07-2025
- Politics
- Hans India
BJP alleges irregularities in machinery purchase in TTD
Tirupati: BJP senior leader and TTD trust board member G Bhanu Prakash Reddy alleged irregularities in the purchase of machinery by TTD for its Srinivasa Ayurvedic Pharmacy located in Srinivasa Mangapuram 12 km from here. Speaking to media persons here on Monday, Bhanu Prakash said in 2022, machines with total cost of Rs 3.9 crore were purchased for production of Ayurvedic medicines, including powder and also tablets but they were of inferior quality. All the machines like grinders, packaging machines broke down resulting in loss to TTD. The machinery was purchased as part of increasing the production of Ayurvedic medicines in Srinivasa Pharmacy set up by TTD for its Ayurvedic Hospitals and also Ayush(Government of India) to get revenue to TTD. Surprisingly, the TTD authorities remained silent on the defective machines causing loss to TTD. He alleged that this was due to political pressure as the supplier of the machines enjoyed the support of the then ruling YSRCP leaders and the machines were purchased for the Srinivasa Pharmacy to benefit a YSRCP leader, he alleged. Bhanu Prakash Reddy said he had already brought the irregularities in the Srinivasa Pharmacy machines purchase to TTD chairman's notice to order an inquiry. On his part, Reddy said he is filing a complaint with the police in a day or two on the irregularities. He dared the former TTD chairman and YSRCP senior leader Y V Subba Reddy, during whose tenure machines were bought, and his successor Bhumana Karunakar Reddy for public debate on the irregularities that took place in TTD during YSRCP period. 'The entire 5 year rule of YSRCP was full of scams in TTD, be it Parakamani, Thulabharam, various constructions and purchase of machinery in SVIMS and in Srinivasa Pharmacy,' he said, adding that the NDA alliance will unearth all these and see all the guilty were punished.
The Hindu
22-05-2025
- Entertainment
- The Hindu
Mohanlal's biography ‘Mukharagam' set for December release
Mohanlal's biography, titled 'Mukharagam', is set for a December 2025 release. The book on the Malayalam superstar is written by Bhanu Prakash and published by Mathrubhumi Books. Mohanlal posted about the biography on social media on his 65th birthday on May 21, 2025 (Wednesday). Spanning over 1000 pages, the biography is set to cover Mohanlal's illustrious journey in the film industry, starting from his debut Thiranottam (1978) till his latest blockbuster Thudarum. 'On the occasion of my birthday, I want to share this happy news that my biography, titled Mukharagam, is set to be released soon. Writer Bhanu Prakash, who has travelled with me in my long journey of 47 years, has chronicled the different stages of my career,' Mohanalal says in a video. The book is set to cover the early life of the actor in Pathanamthitta apart from talking about his popular films. It will also have behind-the-scene accounts of his noted projects. ALSO READ:Mohanlal turns 65, announces liver transplant aid, anti-drug drive Meanwhile, after the humungous success of the Tharun Moorthy-directorial Thudarum, the actoris awaiting the releases of Vrusshabha and Hridayapoorvam. While the former is directed by Kannada filmmaker Nanda Kishore, the latter reunites the hit pair of Mohanlal and director Sathyan Anthikad.
